Explore the vast range of titles available.

The H1 data preservation project was started in 2009 as part of the global data preservation initiative in high-energy physics, DPHEP. In order to retain the full potential for future improvements, the H1 Collaboration aims for level 4 of the DPHEP recommendations, which requires the full simulation and reconstruction chain as well as the data to be preserved for future analysis. A major goal of the H1 project is therefore to provide secure, long-lived and validated access to the H1 data and analysis software, which is realised in collaboration with DESY-IT using virtualisation techniques. By implementing such a system, it is hoped that the lifetime of the unique ep collision data from HERA will be extended, providing the possibility for novel analysis in the future. The preservation of the data and software is performed alongside a consolidation programme of digital and non-digital documentation, some of which dates back to the early 1980s. A new organisational model of the H1 Collaboration, reflecting the change to the long term phase, is to be adopted in July 2012.

Data from high-energy physics experiments are collected with significant financial and human effort and are mostly unique. However, until recently no coherent strategy existed for data preservation and re-use, and many important and complex data sets have simply been lost. While the current focus is on the LHC at CERN, in the current period several important and unique experimental programs at other facilities are coming to an end, including those at HERA, b-factories and the Tevatron. To address this issue, an inter-experimental study group on HEP data preservation and long-term analysis (DPHEP) was convened at the end of 2008. The group now aims to publish a full and detailed review of the present status of data preservation in high energy physics. This contribution summarises the results of the DPHEP study group, describing the challenges of data preservation in high energy physics and the group's first conclusions and recommendations. The physics motivation for data preservation, generic computing and preservation models, technological expectations and governance aspects at local and international levels are examined.

Preoperative chemoradiotherapy with infusional fluorouracil, total mesorectal excision surgery, and postoperative chemotherapy with fluorouracil was established by the German CAO/ARO/AIO-94 trial as a standard combined modality treatment for locally advanced rectal cancer. Here we compare the previously established regimen with an investigational regimen in which oxaliplatin was added to both preoperative chemoradiotherapy and postoperative chemotherapy. In this multicentre, open-label, randomised, phase 3 study we randomly assigned patients with rectal adenocarcinoma, clinically staged as cT3–4 or any node-positive disease, to two groups: a control group receiving standard fluorouracil-based combined modality treatment, consisting of preoperative radiotherapy of 50·4 Gy in 28 fractions plus infusional fluorouracil (1000 mg/m2 on days 1–5 and 29–33), followed by surgery and four cycles of bolus fluorouracil (500 mg/m2 on days 1–5 and 29); or to an investigational group receiving preoperative radiotherapy of 50·4 Gy in 28 fractions plus infusional fluorouracil (250 mg/m2 on days 1–14 and 22–35) and oxaliplatin (50 mg/m2 on days 1, 8, 22, and 29), followed by surgery and eight cycles of oxaliplatin (100 mg/m2 on days 1 and 15), leucovorin (400 mg/m2 on days 1 and 15), and infusional fluorouracil (2400 mg/m2 on days 1–2 and 15–16). Randomisation was done with computer-generated block-randomisation codes stratified by centre, clinical T category (cT1–3 vs cT4), and clinical N category (cN0 vs cN1–2) without masking. The primary endpoint was disease-free survival, defined as the time between randomisation and non-radical surgery of the primary tumour (R2 resection), locoregional recurrence after R0/1 resection, metastatic disease or progression, or death from any cause, whichever occurred first. Survival and cumulative incidence of recurrence analyses followed the intention-to-treat principle; toxicity analyses included all patients treated. Enrolment of patients in this trial is completed and follow-up is ongoing. This study is registered with ClinicalTrials.gov, number NCT00349076. Of the 1265 patients initially enrolled, 1236 were assessable (613 in the investigational group and 623 in the control group). With a median follow-up of 50 months (IQR 38–61), disease-free survival at 3 years was 75·9% (95% CI 72·4–79·5) in the investigational group and 71·2% (95% CI 67·6–74·9) in the control group (hazard ratio [HR] 0·79, 95% CI 0·64–0·98; p=0·03). Preoperative grade 3–4 toxic effects occurred in 144 (24%) of 607 patients who actually received fluorouracil and oxaliplatin during chemoradiotherapy and in 128 (20%) of 625 patients who actually received fluorouracil chemoradiotherapy. Of 445 patients who actually received adjuvant fluorouracil and leucovorin and oxaliplatin, 158 (36%) had grade 3–4 toxic effects, as did 170 (36%) of 470 patients who actually received adjuvant fluorouracil. Late grade 3–4 adverse events in patients who received protocol-specified preoperative and postoperative treatment occurred in 112 (25%) of 445 patients in the investigational group, and in 100 (21%) of 470 patients in the control group. Adding oxaliplatin to fluorouracil-based neoadjuvant chemoradiotherapy and adjuvant chemotherapy (at the doses and intensities used in this trial) significantly improved disease-free survival of patients with clinically staged cT3–4 or cN1–2 rectal cancer compared with our former fluorouracil-based combined modality regimen (based on CAO/ARO/AIO-94). The regimen established by CAO/ARO/AIO-04 can be deemed a new treatment option for patients with locally advanced rectal cancer. German Cancer Aid (Deutsche Krebshilfe).

Measurements of open charm and beauty production cross sections in deep inelastic ep scattering at HERA from the H1 and ZEUS Collaborations are combined. Reduced cross sections are obtained in the kinematic range of negative four-momentum transfer squared of the photon 2.5GeV2≤Q2≤2000GeV2 and Bjorken scaling variable 3·10-5≤xBj≤5·10-2. The combination method accounts for the correlations of the statistical and systematic uncertainties among the different datasets. Perturbative QCD calculations are compared to the combined data. A next-to-leading order QCD analysis is performed using these data together with the combined inclusive deep inelastic scattering cross sections from HERA. The running charm- and beauty-quark masses are determined as mc(mc)=1.290-0.041+0.046(exp/fit)-0.014+0.062(model)-0.031+0.003(parameterisation) GeV and mb(mb)=4.049-0.109+0.104(exp/fit)-0.032+0.090(model)-0.031+0.001(parameterisation)GeV.

Preoperative chemoradiotherapy, total mesorectal excision surgery, and adjuvant chemotherapy with fluorouracil is the standard combined modality treatment for rectal cancer. With the aim of improving disease-free survival (DFS), this phase 3 study (CAO/ARO/AIO-04) integrated oxaliplatin into standard treatment. This was a multicentre, open-label, randomised, phase 3 study in patients with histologically proven carcinoma of the rectum with clinically staged T3–4 or any node-positive disease. Between July 25, 2006, and Feb 26, 2010, patients were randomly assigned to two groups: a control group receiving standard fluorouracil-based combined modality treatment, consisting of preoperative radiotherapy of 50·4 Gy plus infusional fluorouracil (1000 mg/m2 days 1–5 and 29–33), followed by surgery and four cycles of bolus fluorouracil (500 mg/m2 days 1–5 and 29; fluorouracil group); and an experimental group receiving preoperative radiotherapy of 50·4 Gy plus infusional fluorouracil (250 mg/m2 days 1–14 and 22–35) and oxaliplatin (50 mg/m2 days 1, 8, 22, and 29), followed by surgery and eight cycles of adjuvant chemotherapy with oxaliplatin (100 mg/m2 days 1 and 15), leucovorin (400 mg/m2 days 1 and 15), and infusional fluorouracil (2400 mg/m2 days 1–2 and 15–16; fluorouracil plus oxaliplatin group). Randomisation was done with computer-generated block-randomisation codes stratified by centre, clinical T category (cT1–4 vs cT4), and clinical N category (cN0 vs cN1–2) without masking. DFS is the primary endpoint. Secondary endpoints, including toxicity, compliance, and histopathological response are reported here. Safety and compliance analyses included patients as treated, efficacy endpoints were analysed according to the intention-to-treat principle. This study is registered with ClinicalTrials.gov, number NCT00349076. Of the 1265 patients initially enrolled, 1236 were evaluable (613 in the fluorouracil plus oxaliplatin group and 623 in the fluorouracil group). Preoperative grade 3–4 toxic effects occurred in 140 (23%) of 606 patients who actually received fluorouracil and oxaliplatin during chemoradiotherapy and in 127 (20%) of 624 patients who actually received fluorouracil chemoradiotherapy. Grade 3–4 diarrhoea was more common in those who received fluorouracil and oxaliplatin during chemoradiotherapy than in those who received fluorouracil during chemoradiotherapy (73 patients [12%] vs 52 patients [8%]), as was grade 3–4 nausea or vomiting (23 [4%] vs nine [1%]). 516 (85%) of the 606 patients who received fluorouracil and oxaliplatin-based chemoradiotherapy had the full dose of chemotherapy, and 571 (94%) had the full dose of radiotherapy; as did 495 (79%) and 601 (96%) of 624 patients who received fluorouracil-based chemoradiotherapy, respectively. A pathological complete response was achieved in 103 (17%) of 591 patients who underwent surgery in the fluorouracil and oxaliplatin group and in 81 (13%) of 606 patients who underwent surgery in the fluorouracil group (odds ratio 1·40, 95% CI 1·02–1·92; p=0·038). In the fluorouracil and oxaliplatin group, 352 (81%) of 435 patients who began adjuvant chemotherapy completed all cycles (with or without dose reduction), as did 386 (83%) of 463 patients in the fluorouracil group. Inclusion of oxaliplatin into modified fluorouracil-based combined modality treatment was feasible and led to more patients achieving a pathological complete response than did standard treatment. Longer follow-up is needed to assess DFS. German Cancer Aid (Deutsche Krebshilfe).

Cross sections for elastic and proton-dissociative photoproduction of J / ψ mesons are measured with the H1 detector in positron-proton collisions at HERA. The data were collected at ep centre-of-mass energies and , corresponding to integrated luminosities of and , respectively. The cross sections are measured as a function of the photon-proton centre-of-mass energy in the range 25< W γp <110 GeV. Differential cross sections d σ /d t , where t is the squared four-momentum transfer at the proton vertex, are measured in the range | t |<1.2 GeV 2 for the elastic process and | t |<8 GeV 2 for proton dissociation. The results are compared to other measurements. The W γp and t -dependences are parametrised using phenomenological fits.

A combination is presented of the inclusive deep inelastic cross sections measured by the H1 and ZEUS Collaborations in neutral and charged current unpolarised e ± p scattering at HERA during the period 1994-2000. The data span six orders of magnitude in negative four-momentum-transfer squared, Q 2 , and in Bjorken x . The combination method used takes the correlations of systematic uncertainties into account, resulting in an improved accuracy. The combined data are the sole input in a NLO QCD analysis which determines a new set of parton distributions, HERAPDF1.0, with small experimental uncertainties. This set includes an estimate of the model and parametrisation uncertainties of the fit result.

The HERAPDF2.0 ensemble of parton distribution functions (PDFs) was introduced in 2015. The final stage is presented, a next-to-next-to-leading-order (NNLO) analysis of the HERA data on inclusive deep inelastic ep scattering together with jet data as published by the H1 and ZEUS collaborations. A perturbative QCD fit, simultaneously of αs(MZ2) and the PDFs, was performed with the result αs(MZ2)=0.1156±0.0011(exp)-0.0002+0.0001(model+parameterisation)±0.0029(scale). The PDF sets of HERAPDF2.0Jets NNLO were determined with separate fits using two fixed values of αs(MZ2), αs(MZ2)=0.1155 and 0.118, since the latter value was already chosen for the published HERAPDF2.0 NNLO analysis based on HERA inclusive DIS data only. The different sets of PDFs are presented, evaluated and compared. The consistency of the PDFs determined with and without the jet data demonstrates the consistency of HERA inclusive and jet-production cross-section data. The inclusion of the jet data reduced the uncertainty on the gluon PDF. Predictions based on the PDFs of HERAPDF2.0Jets NNLO give an excellent description of the jet-production data used as input.

Measurements of open charm production cross sections in deep-inelastic ep scattering at HERA from the H1 and ZEUS Collaborations are combined. Reduced cross sections for charm production are obtained in the kinematic range of photon virtuality 2.5≤ Q 2 ≤2000 GeV 2 and Bjorken scaling variable 3⋅10 −5 ≤ x ≤5⋅10 −2 . The combination method accounts for the correlations of the systematic uncertainties among the different data sets. The combined charm data together with the combined inclusive deep-inelastic scattering cross sections from HERA are used as input for a detailed NLO QCD analysis to study the influence of different heavy flavour schemes on the parton distribution functions. The optimal values of the charm mass as a parameter in these different schemes are obtained. The implications on the NLO predictions for W ± and Z production cross sections at the LHC are investigated. Using the fixed flavour number scheme, the running mass of the charm quark is determined.

A precision measurement of jet cross sections in neutral current deep-inelastic scattering for photon virtualities 5.5 < Q 2 < 80 GeV 2 and inelasticities 0.2 < y < 0.6 is presented, using data taken with the H1 detector at HERA, corresponding to an integrated luminosity of 290 pb - 1 . Double-differential inclusive jet, dijet and trijet cross sections are measured simultaneously and are presented as a function of jet transverse momentum observables and as a function of Q 2 . Jet cross sections normalised to the inclusive neutral current DIS cross section in the respective Q 2 -interval are also determined. Previous results of inclusive jet cross sections in the range 150 < Q 2 < 15 , 000 GeV 2 are extended to low transverse jet momenta 5 < P T jet < 7 GeV . The data are compared to predictions from perturbative QCD in next-to-leading order in the strong coupling, in approximate next-to-next-to-leading order and in full next-to-next-to-leading order. Using also the recently published H1 jet data at high values of Q 2 , the strong coupling constant α s ( M Z ) is determined in next-to-leading order.